StockMacro
Company, fund or insider

Help

Menu

Denali Therapeutics

$18.45 -4.8% in 6 monthsMarket cap $3.0B

DNLI on XNAS, Health Care, Denali Therapeutics Inc., job postings

Measures activity, not value. Not investment advice.

News coverage hit 7.0 times its usual week while Denali lost $314.4M and burned $450M in cash over 12 months.

  • GoodShares up 7.5% over 12 months but down 1.2% in one month
  • WatchShort interest 9.2% of shares, down 5.0% from two weeks earlier

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
507
Website
denalitherapeutics.com
Listed
Nasdaq, US
Last results
3 Nov 2026
Next results
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $17.8M, net income $70.1M.
Quarter to 31 Dec 2021: revenue $12.5M, net income -$75.3MQuarter to 31 Dec 2021: revenue $12.5M, net income -$75.3MQuarter to 31 Mar 2022: revenue $42.1M, net income -$65.2MQuarter to 31 Mar 2022: revenue $42.1M, net income -$65.2MQuarter to 30 Jun 2022: revenue $52.5M, net income -$58.8MQuarter to 30 Jun 2022: revenue $52.5M, net income -$58.8MQuarter to 30 Sep 2022: revenue $3.6M, net income -$103.3MQuarter to 30 Sep 2022: revenue $3.6M, net income -$103.3MQuarter to 31 Dec 2022: revenue $10.3M, net income -$98.7MQuarter to 31 Dec 2022: revenue $10.3M, net income -$98.7MQuarter to 31 Mar 2023: revenue $35.1M, net income -$109.8MQuarter to 31 Mar 2023: revenue $35.1M, net income -$109.8MQuarter to 30 Jun 2023: revenue $294.1M, net income $183.4MQuarter to 30 Jun 2023: revenue $294.1M, net income $183.4MQuarter to 30 Sep 2023: revenue $1.3M, net income -$99.4MQuarter to 30 Sep 2023: revenue $1.3M, net income -$99.4MQuarter to 31 Dec 2023: revenue –, net income -$119.5MQuarter to 31 Mar 2024: revenue $0, net income -$101.8MQuarter to 31 Mar 2024: revenue $0, net income -$101.8MQuarter to 30 Jun 2024: revenue $0, net income -$99.0MQuarter to 30 Jun 2024: revenue $0, net income -$99.0MQuarter to 30 Sep 2024: revenue $0, net income -$107.2MQuarter to 30 Sep 2024: revenue $0, net income -$107.2MQuarter to 31 Dec 2024: revenue $0, net income -$114.8MQuarter to 31 Dec 2024: revenue $0, net income -$114.8MQuarter to 31 Mar 2025: revenue –, net income -$133.0MQuarter to 30 Jun 2025: revenue $0, net income -$124.1MQuarter to 30 Jun 2025: revenue $0, net income -$124.1MQuarter to 30 Sep 2025: revenue $0, net income -$126.9MQuarter to 30 Sep 2025: revenue $0, net income -$126.9MQuarter to 31 Dec 2025: revenue $0, net income -$128.5MQuarter to 31 Dec 2025: revenue $0, net income -$128.5MQuarter to 31 Mar 2026: revenue –, net income -$128.4MQuarter to 30 Jun 2026: revenue $3.6M, net income -$127.6MQuarter to 30 Jun 2026: revenue $3.6M, net income -$127.6MQuarter to 30 Sep 2026: revenue $17.8M, net income $70.1MQuarter to 30 Sep 2026: revenue $17.8M, net income $70.1M
31 Dec 2021RevenueNet incomeNet losstallest bar $294.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$17.8M$70.1M
30 Jun 2026$3.6M-$127.6M
31 Mar 2026–-$128.4M
31 Dec 2025$0-$128.5M
30 Sep 2025$0-$126.9M
30 Jun 2025$0-$124.1M
31 Mar 2025–-$133.0M
31 Dec 2024$0-$114.8M
30 Sep 2024$0-$107.2M
30 Jun 2024$0-$99.0M
31 Mar 2024$0-$101.8M
31 Dec 2023–-$119.5M
30 Sep 2023$1.3M-$99.4M
30 Jun 2023$294.1M$183.4M
31 Mar 2023$35.1M-$109.8M
31 Dec 2022$10.3M-$98.7M
30 Sep 2022$3.6M-$103.3M
30 Jun 2022$52.5M-$58.8M
31 Mar 2022$42.1M-$65.2M
31 Dec 2021$12.5M-$75.3M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$314.4M -$498.7M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$1.73 -$2.92
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -33.9% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$450.0M –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $516.2M $848.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$516.2M (net cash) -$848.2M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $5.78
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 3.2 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Denali TherapeuticsDNLI (this company) $3.0Bloss–––
VericelVCEL $2.9B88.19.1+25%10.3%
ADMA BiologicsADMA $2.9B16.05.6+6.3%35.1%
Iovance BiotherapeuticsIOVA $3.2Bloss8.4+51%-58.2%
Relay TherapeuticsRLAY $3.6Bloss–––
Tarsus PharmaceuticalsTARS $3.6Bloss5.3+86%-103%

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$364K

bought $0, sold $364K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-1.0%

283 13F filers vs 286

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

95%

152.0M shares held by 13F filers (30 Sep 2026) of 160.3M outstanding (28 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

9.2%

14.7M shares sold short (30 Oct 2026) of 160.3M outstanding (28 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

9.9

14.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-5.0%

15.5M shares sold short in the report before, 14.7M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

62%

62% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 58%

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$280K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

15

15 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

7.5×

15 articles in the last 7 days; its usual week has 2.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Revenue $17.8M

Price $18.45 on 20 Nov 2026, +7.5% over 12 months (12-month range $16.02 to $27.21)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $1.3M in the last 12 months (the 12 months before: -$9.6M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 6 published in the last 12 months, -33% on the 12 months before.
Revenue per quarter. Revenue $17.8M in the latest quarter.
Capital spending per quarter. Capital spending $1.0M in the latest quarter.
Institutional holders (13F filers). 283 13F filers reported holding it in the latest 13F quarter, +24% on a year earlier.
Lobbying spend. Lobbying spend: $280K published in the last 12 months, +37% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
5 Nov 2026Sharp changeQuarterly revenue change: quarterly revenue change, 17.8M vs usual 0 (2026-09-30)
28 Jul 20268-K and other filingsCompleted an acquisition or asset sale
3 Apr 20268-K and other filingsA major agreement ended
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 41 vs usual 30 (2025-12-31); 1.4x the same period a year earlier
14 Aug 2025Sharp changeMany funds opening a new position: many funds opening a new position, 42 vs usual 28.50 (2025-06-30); 1.6x the same period a year earlier
17 Jun 2025Sharp changeShort interest spike: short interest spike, 12.2M vs usual 8.2M (2025-05-30); 1.3x the same period a year earlier
29 Apr 2025Sharp changeShort interest spike: short interest spike, 13.0M vs usual 8.2M (2025-04-15); 1.4x the same period a year earlier
14 Apr 2025Lobbying filingnew lobbying registration (MANATT, PHELPS, AND PHILLIPS)
14 Apr 2025Sharp changeFirst lobbying registration: first lobbying registration: DENALI THERAPEUTICS: new lobbying registration (MANATT, PHELPS, AND PHILLIPS)
27 Feb 20258-K and other filingsA major agreement ended
1 Mar 20248-K and other filingsPrivate placement of securities (Form D)
15 Aug 2023Sharp changeQuarterly revenue change: quarterly revenue change, 294.1M vs usual 16.6M (2023-06-30); 5.6x the same period a year earlier
9 Aug 2022Sharp changeQuarterly revenue change: quarterly revenue change, 52.5M vs usual 6.9M (2022-06-30); 2.3x the same period a year earlier
28 Jun 2022Sharp changeShort interest spike: short interest spike, 7.8M vs usual 5.7M (2022-06-15); 1.5x the same period a year earlier
14 Jun 2022Sharp changeShort interest spike: short interest spike, 7.8M vs usual 5.7M (2022-05-31); 1.4x the same period a year earlier
10 May 2022Sharp changeQuarterly revenue change: quarterly revenue change, 42.1M vs usual 6.9M (2022-03-31); 5.3x the same period a year earlier
16 Mar 20228-K and other filingsDirector or officer change
7 Feb 20228-K and other filingsDirector or officer change
7 Feb 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$4.1M published
Month from 1 Jan 2022: -$579K published
Month from 1 Feb 2022: -$873K published
Month from 1 Mar 2022: -$677K published
Month from 1 Jul 2022: -$712K published
Month from 1 Aug 2022: -$1.0M published
Month from 1 Oct 2022: -$616K published
Month from 1 Nov 2022: -$1.2M published
Month from 1 Jan 2023: -$1.1M published
Month from 1 Feb 2023: -$2.3M published
Month from 1 Apr 2023: -$879K published
Month from 1 May 2023: -$286K published
Month from 1 Jun 2023: -$1.6M published
Month from 1 Jul 2023: -$686K published
Month from 1 Aug 2023: -$686K published
Month from 1 Sep 2023: -$39K published
Month from 1 Oct 2023: -$34K published
Month from 1 Nov 2023: -$32K published
Month from 1 Dec 2023: -$39K published
Month from 1 Jan 2024: -$1.1M published
Month from 1 Feb 2024: -$719K published
Month from 1 Mar 2024: -$33K published
Month from 1 Apr 2024: -$1.9M published
Month from 1 May 2024: -$34K published
Month from 1 Jun 2024: -$32K published
Month from 1 Jul 2024: -$747K published
Month from 1 Aug 2024: -$951K published
Month from 1 Sep 2024: -$108K published
Month from 1 Oct 2024: -$2.0M published
Month from 1 Nov 2024: -$2.5M published
Month from 1 Jan 2025: -$2.1M published
Month from 1 Jul 2025: -$7.4M published
Month from 1 Aug 2025: -$92K published
Month from 1 Jan 2026: -$865K published
Month from 1 Aug 2026: -$72K published
Month from 1 Sep 2026: -$364K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 2 published
Quarter from 1 Apr 2022: 1 published
Quarter from 1 Jul 2022: 6 published
Quarter from 1 Oct 2022: 3 published
Quarter from 1 Jan 2023: 2 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Oct 2023: 2 published
Quarter from 1 Apr 2024: 1 published
Quarter from 1 Jul 2024: 2 published
Quarter from 1 Oct 2024: 4 published
Quarter from 1 Jan 2025: 1 published
Quarter from 1 Apr 2025: 2 published
Quarter from 1 Jul 2025: 5 published
Quarter from 1 Oct 2025: 1 published
Quarter from 1 Jan 2026: 3 published
Quarter from 1 Jul 2026: 2 published
Quarter from 1 Oct 2026: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $12.5M, -96% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $42.1M, +432% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $52.5M, +129% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $3.6M, -33% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $10.3M, -18% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $35.1M, -17% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $294.1M, +460% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $1.3M, -64% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $0, -100% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $0, -100% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $0; public on 28 Feb 2025
Quarter ended 30 Jun 2025: $0; public on 7 Aug 2026
Quarter ended 30 Sep 2025: $0; public on 4 Nov 2026
Quarter ended 31 Dec 2025: $0; public on 27 Feb 2026
Quarter ended 30 Jun 2026: $3.6M; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $17.8M; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $3.1M, +155% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $4.0M, +44% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $2.9M, +275% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $6.0M, +223% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $4.8M, +59% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $2.8M, -31% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $5.8M, +102% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $2.1M, -66% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $2.2M, -54% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2024: $2.1M, -23% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $4.8M, -18% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $3.9M, +88% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $5.1M, +128% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $5.1M, +136% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $4.3M, -11% on a year earlier; public on 12 Aug 2025
Quarter ended 31 Dec 2025: $1.5M, -70% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $2.5M, -51% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $805K, -81% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $1.0M; public on 4 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 194; public on 14 Feb 2022
31 Mar 2022 report: 177; public on 16 May 2022
30 Jun 2022 report: 176; public on 15 Aug 2022
30 Sep 2022 report: 185; public on 14 Nov 2022
31 Dec 2022 report: 185; public on 14 Feb 2023
31 Mar 2023 report: 190; public on 15 May 2023
30 Jun 2023 report: 187; public on 14 Aug 2023
30 Sep 2023 report: 177; public on 14 Nov 2023
31 Dec 2023 report: 197; public on 14 Feb 2024
31 Mar 2024 report: 200; public on 15 May 2024
30 Jun 2024 report: 189; public on 14 Aug 2024
30 Sep 2024 report: 208; public on 14 Nov 2024
31 Dec 2024 report: 221; public on 14 Feb 2025
31 Mar 2025 report: 214; public on 15 May 2025
30 Jun 2025 report: 220; public on 14 Aug 2025
30 Sep 2025 report: 229; public on 14 Nov 2025
31 Dec 2025 report: 243; public on 17 Feb 2026
31 Mar 2026 report: 259; public on 15 May 2026
30 Jun 2026 report: 286; public on 14 Aug 2026
30 Sep 2026 report: 283; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2025: $68K published
Quarter from 1 Jul 2025: $68K published
Quarter from 1 Oct 2025: $70K published
Quarter from 1 Jan 2026: $70K published
Quarter from 1 Apr 2026: $70K published
Quarter from 1 Jul 2026: $70K published
Quarter from 1 Oct 2026: $70K published

What is unusual now

  • Made public in the last 90 days: it reported revenue of $17.8M for the quarter ended 30 Sep 2026, against none in the same quarter last year.
  • Quarterly revenue change: reported revenue of $17.8M for the quarter ended 30 Sep 2026, against none in the same quarter last year Public on 5 Nov 2026.
  • Insider net buying (open market): Insiders sold a net $1.3M in the last 12 months (the 12 months before: -$9.6M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 6 published in the last 12 months, -33% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 3 sales, $364K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
9 Sep 2026Peter Scott ChinChief Medical OfficerSell1,654$22.29$37KForm 4
4 Sep 2026Nancy ThornberryDirectorSellplanned in advance (10b5-1)11,439$22.90$262KForm 4
3 Sep 2026Alexander O. SchuthCOFO and SecretarySellplanned in advance (10b5-1)2,768$23.44$65KForm 4
13 Aug 2026Alexander O. SchuthCOFO and SecretarySell2,857$25.07$72KForm 4
8 Jan 2026Ryan J. WattsPresident and CEOSell35,198$16.50$581KForm 4
8 Jan 2026Alexander O. SchuthCOFO and SecretarySell17,218$16.50$284KForm 4
14 Aug 2025Alexander O. SchuthCOFO and SecretarySell2,937$13.58$40KForm 4
14 Aug 2025Carole HoChief Medical OfficerSellplanned in advance (10b5-1)3,743$13.81$52KForm 4

283 institutions reported shares at the end of Q3 2026, 95% of the shares outstanding; 34 opened a position, 37 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
T. Rowe Price Investment Management, Inc.19.6M12.2%+3.4M+21%
BlackRock, Inc.14.3M8.94%$296.2M+302K+2.2%
Baillie Gifford & Co11.1M6.94%$229.8M-840K-7.0%
Temasek Holdings (Private) Ltd7.0M4.38%$145.0MNo change
Vanguard Portfolio Management LLC6.8M4.22%$139.7M+281K+4.3%
Vanguard Capital Management LLC6.8M4.21%$139.5M+475K+7.6%
State Street Corp6.7M4.17%$138.1M-367K-5.2%
FMR LLC (Fidelity)4.5M2.83%$93.7M-2,715-0.1%
Geode Capital Management, LLC4.0M2.52%$83.5M+65K+1.6%
Goldman Sachs Group Inc3.8M2.34%$77.6M-401K-9.7%

Company events

All 30 company events

In 12 months: 3 major agreements, 1 agreement ended, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
27 Jul 2026Completed an acquisition or asset sale8-K
18 Jun 2026Signed a major agreement8-K
3 Apr 2026A major agreement ended8-K
10 Dec 2025Signed a major agreement8-K
4 Dec 2025Signed a major agreement8-K
3 Jun 2025Signed a major agreementSame filing: shareholder vote results8-K
27 Feb 2025Signed a major agreement; A major agreement ended8-K
1 Mar 2024Private placement of securities (Form D)$499.7M sold of $499.7M offeredD

Reported lobbying spend: $70K in Q3 2026, $70K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Jan 2025NewManatt, Phelps, And Phillipsfor Denali TherapeuticsRare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug developmentHealth issuesFiling

The 5 newest of 186 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

29 Apr 2025confirmed

Confirmed across sources Lobbying and Short interest and volume

Denali Therapeutics (DNLI): registered for federal lobbying for the first time in our data (Manatt, Phelps, And Phillips), while it had 13.0M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year. Two unrelated kinds of activity within 15 days.

  • Lobbying: First lobbying registration, became public on 14 Apr 2025
  • Short interest and volume: Short interest spike, became public on 26 Apr 2025
2024-04-15: 9.6M2024-04-30: 10.5M2024-05-15: 9.5M2024-05-31: 9.3M2024-06-14: 8.9M2024-06-28: 7.4M2024-07-15: 7.1M2024-07-31: 7.2M2024-08-15: 8.4M2024-08-30: 9.0M2024-09-13: 9.4M2024-09-30: 7.7M2024-10-15: 7.7M2024-10-31: 7.4M2024-11-15: 7.1M2024-11-29: 7.4M2024-12-13: 7.5M2024-12-31: 7.8M2025-01-15: 8.0M2025-01-31: 7.7M2025-02-14: 8.7M2025-02-28: 8.9M2025-03-14: 10.5M2025-03-31: 11.4M2025-04-15: 13.0M
The 15 Apr 2025 report against the 24 reports before it. this reportearliernormal: 8.2M
See the evidence (2 changes)

Lobbying: First lobbying registration became public on 14 Apr 2025

Denali Therapeutics registered for federal lobbying for the first time in our data (Manatt, Phelps, And Phillips).

Source coverage starts
7 Oct 2008
Earlier events of other kinds
0

"First" means first in our data: it fires only when the source's history began at least 365 days earlier.

Short interest and volume: Short interest spike became public on 26 Apr 2025

Denali Therapeutics had 13.0M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.

This period
13.0M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
8.2M
Typical spread (median absolute deviation)
765K
How far from its usual level
+4.3
Same report last year
9.6M
History used
2,664 days
2024-04-15: 9.6M2024-04-30: 10.5M2024-05-15: 9.5M2024-05-31: 9.3M2024-06-14: 8.9M2024-06-28: 7.4M2024-07-15: 7.1M2024-07-31: 7.2M2024-08-15: 8.4M2024-08-30: 9.0M2024-09-13: 9.4M2024-09-30: 7.7M2024-10-15: 7.7M2024-10-31: 7.4M2024-11-15: 7.1M2024-11-29: 7.4M2024-12-13: 7.5M2024-12-31: 7.8M2025-01-15: 8.0M2025-01-31: 7.7M2025-02-14: 8.7M2025-02-28: 8.9M2025-03-14: 10.5M2025-03-31: 11.4M2025-04-15: 13.0M
the 15 Apr 2025 report24 earlier reportsnormal: 8.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 5 Nov 2026Financials change

    reported revenue of $17.8M for the quarter ended 30 Sep 2026, against none in the same quarter last year.

    See the evidence
    This period
    $17.8M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $0
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +17.8
    Same quarter last year
    $0
    History used
    3,379 days
    2024-03-31: $02024-06-30: $02024-09-30: $02024-12-31: $02025-06-30: $02025-09-30: $02025-12-31: $02026-06-30: $3.6M2026-09-30: $17.8M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $0

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  2. 28 Jul 2026Filings record

    Completed an acquisition or asset sale (dated 27 Jul 2026)

  3. 3 Apr 2026Filings record

    A major agreement ended

  4. 17 Feb 2026Institutional holdings change

    saw 41 13F filers open a new position in the quarter ended 31 Dec 2025, 1.4× the same quarter last year.

    Same quarter last year: 29; its normal quarter is 30.

    See the evidence
    This period
    41 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    30
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +3.7
    Same quarter last year
    29
    History used
    2,922 days
    2023-12-31: 282024-03-31: 302024-06-30: 262024-09-30: 302024-12-31: 292025-03-31: 332025-06-30: 422025-09-30: 312025-12-31: 41
    the quarter ended 31 Dec 20258 earlier quartersnormal: 30

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  5. 14 Aug 2025Institutional holdings change

    saw 42 13F filers open a new position in the quarter ended 30 Jun 2025, 1.6× the same quarter last year.

    Same quarter last year: 26; its normal quarter is 28.5.

    See the evidence
    This period
    42 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    28.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +4.5
    Same quarter last year
    26
    History used
    2,738 days
    2023-06-30: 222023-09-30: 232023-12-31: 282024-03-31: 302024-06-30: 262024-09-30: 302024-12-31: 292025-03-31: 332025-06-30: 42
    the quarter ended 30 Jun 20258 earlier quartersnormal: 28.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  6. 11 Jun 2025Short interest and volume change

    had 12.2M shares sold short in the 30 May 2025 report, 1.3× the same report last year.

    Same report last year: 9.3M; its normal report is 8.2M.

    See the evidence
    This period
    12.2M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    8.2M
    Typical spread (median absolute deviation)
    765K
    How far from its usual level
    +3.6
    Same report last year
    9.3M
    History used
    2,709 days
    2024-05-31: 9.3M2024-06-14: 8.9M2024-06-28: 7.4M2024-07-15: 7.1M2024-07-31: 7.2M2024-08-15: 8.4M2024-08-30: 9.0M2024-09-13: 9.4M2024-09-30: 7.7M2024-10-15: 7.7M2024-10-31: 7.4M2024-11-15: 7.1M2024-11-29: 7.4M2024-12-13: 7.5M2024-12-31: 7.8M2025-01-15: 8.0M2025-01-31: 7.7M2025-02-14: 8.7M2025-02-28: 8.9M2025-03-14: 10.5M2025-03-31: 11.4M2025-04-15: 13.0M2025-04-30: 11.7M2025-05-15: 12.1M2025-05-30: 12.2M
    the 30 May 2025 report24 earlier reportsnormal: 8.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 29 Apr 2025several at once

    registered for federal lobbying for the first time in our data (Manatt, Phelps, And Phillips), while it had 13.0M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year. Two unrelated kinds of activity within 15 days.

    See the evidence (2 changes)

    Lobbying: First lobbying registration became public on 14 Apr 2025

    Denali Therapeutics registered for federal lobbying for the first time in our data (Manatt, Phelps, And Phillips).

    Source coverage starts
    7 Oct 2008
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

    Short interest and volume: Short interest spike became public on 26 Apr 2025

    Denali Therapeutics had 13.0M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.

    This period
    13.0M (the 15 Apr 2025 report)
    Normal report (median of 24 earlier)
    8.2M
    Typical spread (median absolute deviation)
    765K
    How far from its usual level
    +4.3
    Same report last year
    9.6M
    History used
    2,664 days
    2024-04-15: 9.6M2024-04-30: 10.5M2024-05-15: 9.5M2024-05-31: 9.3M2024-06-14: 8.9M2024-06-28: 7.4M2024-07-15: 7.1M2024-07-31: 7.2M2024-08-15: 8.4M2024-08-30: 9.0M2024-09-13: 9.4M2024-09-30: 7.7M2024-10-15: 7.7M2024-10-31: 7.4M2024-11-15: 7.1M2024-11-29: 7.4M2024-12-13: 7.5M2024-12-31: 7.8M2025-01-15: 8.0M2025-01-31: 7.7M2025-02-14: 8.7M2025-02-28: 8.9M2025-03-14: 10.5M2025-03-31: 11.4M2025-04-15: 13.0M
    the 15 Apr 2025 report24 earlier reportsnormal: 8.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  8. 26 Apr 2025Short interest and volume change

    had 13.0M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.

    Same report last year: 9.6M; its normal report is 8.2M.

    See the evidence
    This period
    13.0M (the 15 Apr 2025 report)
    Normal report (median of 24 earlier)
    8.2M
    Typical spread (median absolute deviation)
    765K
    How far from its usual level
    +4.3
    Same report last year
    9.6M
    History used
    2,664 days
    2024-04-15: 9.6M2024-04-30: 10.5M2024-05-15: 9.5M2024-05-31: 9.3M2024-06-14: 8.9M2024-06-28: 7.4M2024-07-15: 7.1M2024-07-31: 7.2M2024-08-15: 8.4M2024-08-30: 9.0M2024-09-13: 9.4M2024-09-30: 7.7M2024-10-15: 7.7M2024-10-31: 7.4M2024-11-15: 7.1M2024-11-29: 7.4M2024-12-13: 7.5M2024-12-31: 7.8M2025-01-15: 8.0M2025-01-31: 7.7M2025-02-14: 8.7M2025-02-28: 8.9M2025-03-14: 10.5M2025-03-31: 11.4M2025-04-15: 13.0M
    the 15 Apr 2025 report24 earlier reportsnormal: 8.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 14 Apr 2025Lobbying change

    registered for federal lobbying for the first time in our data (Manatt, Phelps, And Phillips).

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2008
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  10. 14 Apr 2025Lobbying record

    DENALI THERAPEUTICS: new lobbying registration (MANATT, PHELPS, AND PHILLIPS) (dated 1 Jan 2025)

  11. 27 Feb 2025Filings record

    A major agreement ended

  12. 1 Mar 2024Filings record

    Private placement of securities (Form D)

  13. 15 Aug 2023Financials change

    reported revenue of $294.1M for the quarter ended 30 Jun 2023, 5.6× the same quarter last year.

    Same quarter last year: $52.5M; its normal quarter is $16.6M.

    See the evidence
    This period
    $294.1M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    $16.6M
    Typical spread (median absolute deviation)
    $13.9M
    How far from its usual level
    +13.5
    Same quarter last year
    $52.5M
    History used
    2,191 days
    2021-03-31: $7.9M2021-06-30: $22.9M2021-09-30: $5.3M2022-03-31: $42.1M2022-06-30: $52.5M2022-09-30: $184K2022-12-31: $10.3M2023-03-31: $35.1M2023-06-30: $294.1M
    the quarter ended 30 Jun 20238 earlier quartersnormal: $16.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  14. 9 Aug 2022Financials change

    reported revenue of $52.5M for the quarter ended 30 Jun 2022, 2.3× the same quarter last year.

    Same quarter last year: $22.9M; its normal quarter is $6.9M.

    See the evidence
    This period
    $52.5M (the quarter ended 30 Jun 2022)
    Normal quarter (median of 8 earlier)
    $6.9M
    Typical spread (median absolute deviation)
    $2.4M
    How far from its usual level
    +13.0
    Same quarter last year
    $22.9M
    History used
    1,826 days
    2019-12-31: $4.7M2020-03-31: $3.6M2020-06-30: $5.8M2020-09-30: $9.4M2021-03-31: $7.9M2021-06-30: $22.9M2021-09-30: $5.3M2022-03-31: $42.1M2022-06-30: $52.5M
    the quarter ended 30 Jun 20228 earlier quartersnormal: $6.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  15. 28 Jun 2022Short interest and volume change

    had 7.8M shares sold short in the 15 Jun 2022 report, 1.5× the same report last year.

    Same report last year: 5.4M; its normal report is 5.7M.

    See the evidence
    This period
    7.8M (the 15 Jun 2022 report)
    Normal report (median of 24 earlier)
    5.7M
    Typical spread (median absolute deviation)
    346K
    How far from its usual level
    +3.6
    Same report last year
    5.4M
    History used
    1,629 days
    2021-05-28: 5.7M2021-06-15: 5.4M2021-06-30: 5.5M2021-07-15: 5.1M2021-07-30: 5.5M2021-08-13: 5.7M2021-08-31: 5.8M2021-09-15: 5.8M2021-09-30: 6.5M2021-10-15: 6.0M2021-10-29: 5.6M2021-11-15: 5.5M2021-11-30: 5.2M2021-12-15: 5.7M2022-01-14: 5.4M2022-01-31: 5.5M2022-02-15: 6.6M2022-02-28: 6.5M2022-03-15: 6.7M2022-03-31: 6.7M2022-04-14: 6.6M2022-04-29: 6.7M2022-05-13: 7.4M2022-05-31: 7.8M2022-06-15: 7.8M
    the 15 Jun 2022 report24 earlier reportsnormal: 5.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 10 Jun 2022Short interest and volume change

    had 7.8M shares sold short in the 31 May 2022 report, 1.4× the same report last year.

    Same report last year: 5.7M; its normal report is 5.7M.

    See the evidence
    This period
    7.8M (the 31 May 2022 report)
    Normal report (median of 24 earlier)
    5.7M
    Typical spread (median absolute deviation)
    319K
    How far from its usual level
    +3.6
    Same report last year
    5.7M
    History used
    1,614 days
    2021-05-14: 5.9M2021-05-28: 5.7M2021-06-15: 5.4M2021-06-30: 5.5M2021-07-15: 5.1M2021-07-30: 5.5M2021-08-13: 5.7M2021-08-31: 5.8M2021-09-15: 5.8M2021-09-30: 6.5M2021-10-15: 6.0M2021-10-29: 5.6M2021-11-15: 5.5M2021-11-30: 5.2M2021-12-15: 5.7M2022-01-14: 5.4M2022-01-31: 5.5M2022-02-15: 6.6M2022-02-28: 6.5M2022-03-15: 6.7M2022-03-31: 6.7M2022-04-14: 6.6M2022-04-29: 6.7M2022-05-13: 7.4M2022-05-31: 7.8M
    the 31 May 2022 report24 earlier reportsnormal: 5.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 10 May 2022Financials change

    reported revenue of $42.1M for the quarter ended 31 Mar 2022, 5.3× the same quarter last year.

    Same quarter last year: $7.9M; its normal quarter is $6.9M.

    See the evidence
    This period
    $42.1M (the quarter ended 31 Mar 2022)
    Normal quarter (median of 8 earlier)
    $6.9M
    Typical spread (median absolute deviation)
    $2.4M
    How far from its usual level
    +10.1
    Same quarter last year
    $7.9M
    History used
    1,735 days
    2019-09-30: $13.6M2019-12-31: $4.7M2020-03-31: $3.6M2020-06-30: $5.8M2020-09-30: $9.4M2021-03-31: $7.9M2021-06-30: $22.9M2021-09-30: $5.3M2022-03-31: $42.1M
    the quarter ended 31 Mar 20228 earlier quartersnormal: $6.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  18. 16 Mar 2022Filings record

    Director or officer change

  19. 7 Feb 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 7 Feb 2022Filings record

    Director or officer change

  21. 10 Aug 2021Financials change

    reported revenue of $22.9M for the quarter ended 30 Jun 2021, 3.9× the same quarter last year.

    Same quarter last year: $5.8M; its normal quarter is $5.2M.

    See the evidence
    This period
    $22.9M (the quarter ended 30 Jun 2021)
    Normal quarter (median of 8 earlier)
    $5.2M
    Typical spread (median absolute deviation)
    $1.4M
    How far from its usual level
    +8.7
    Same quarter last year
    $5.8M
    History used
    1,461 days
    2019-03-31: $4.2M2019-06-30: $4.2M2019-09-30: $13.6M2019-12-31: $4.7M2020-03-31: $3.6M2020-06-30: $5.8M2020-09-30: $9.4M2021-03-31: $7.9M2021-06-30: $22.9M
    the quarter ended 30 Jun 20218 earlier quartersnormal: $5.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  22. 16 Feb 2021Institutional holdings change

    saw 51 13F filers open a new position in the quarter ended 31 Dec 2020, 4.6× the same quarter last year.

    Same quarter last year: 11; its normal quarter is 24.5.

    See the evidence
    This period
    51 (the quarter ended 31 Dec 2020)
    Normal quarter (median of 8 earlier)
    24.5
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +4.5
    Same quarter last year
    11
    History used
    1,096 days
    2018-12-31: 222019-03-31: 272019-06-30: 222019-09-30: 142019-12-31: 112020-03-31: 292020-06-30: 282020-09-30: 362020-12-31: 51
    the quarter ended 31 Dec 20208 earlier quartersnormal: 24.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  23. 11 Jan 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  24. 11 Jan 2021Filings record

    Director or officer change

  25. 20 Aug 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 20 Aug 2020Filings record

    Director or officer change

  27. 12 Nov 2019Financials change

    reported revenue of $13.6M for the quarter ended 30 Sep 2019, 11× the same quarter last year.

    Same quarter last year: $1.2M; its normal quarter is $1.4M.

    See the evidence
    This period
    $13.6M (the quarter ended 30 Sep 2019)
    Normal quarter (median of 8 earlier)
    $1.4M
    Typical spread (median absolute deviation)
    $1.4M
    How far from its usual level
    +5.8
    Same quarter last year
    $1.2M
    History used
    822 days
    2017-09-30: $02017-12-31: $02018-03-31: $641K2018-06-30: $1.6M2018-09-30: $1.2M2018-12-31: $125.7M2019-03-31: $4.2M2019-06-30: $4.2M2019-09-30: $13.6M
    the quarter ended 30 Sep 20198 earlier quartersnormal: $1.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  28. 13 Aug 2019Financials change

    spent $10.3M on capital projects in the quarter ended 30 Jun 2019, 18× the same quarter last year.

    Same quarter last year: $572K; its normal quarter is $710K.

    See the evidence
    This period
    $10.3M (the quarter ended 30 Jun 2019)
    Normal quarter (median of 8 earlier)
    $710K
    Typical spread (median absolute deviation)
    $258K
    How far from its usual level
    +9.6
    Same quarter last year
    $572K
    History used
    821 days
    2017-06-30: $569K2017-09-30: $367K2017-12-31: $1.1M2018-03-31: $537K2018-06-30: $572K2018-09-30: $847K2018-12-31: $1.4M2019-03-31: $2.0M2019-06-30: $10.3M
    the quarter ended 30 Jun 20198 earlier quartersnormal: $710K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  29. 19 Mar 2019Financials change

    reported revenue of $125.7M for the quarter ended 31 Dec 2018, against none in the same quarter last year.

    See the evidence
    This period
    $125.7M (the quarter ended 31 Dec 2018)
    Normal quarter (median of 6 earlier)
    $320K
    Typical spread (median absolute deviation)
    $320K
    How far from its usual level
    +125.4
    Same quarter last year
    $0
    History used
    549 days
    2017-06-30: $02017-09-30: $02017-12-31: $02018-03-31: $641K2018-06-30: $1.6M2018-09-30: $1.2M2018-12-31: $125.7M
    the quarter ended 31 Dec 20186 earlier quartersnormal: $320K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  30. 8 Nov 2018Filings record

    Director or officer change

  31. 30 May 2018Filings record

    Completed an acquisition or asset sale

  32. 19 Mar 2018Filings record

    Director or officer change

  33. 15 Dec 2017Insiders record

    Crestline Investors, Inc. (ten percent owner) and 7 other(s) bought 275,000 shares of DNLI ($5.0M) (dated 14 Dec 2017)

  34. 7 Dec 2017Filings record

    Registered new securities for sale (S-1)

  35. 27 Nov 2017Filings record

    Registered new securities for sale (S-1)

  36. 13 Nov 2017Filings record

    Registered new securities for sale (S-1)

Not listed: 348 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001714899
Ticker
DNLI
Domain
denalitherapeutics.com
Employer name
Denali Therapeutics Inc. (1 unverified)
Hq location
CA|SOUTH SAN FRANCISCO|94080 (1 unverified)
Lobbying client
denali therapeutics
Name
Denali BBB Holding Limited, Denali Therapeutics CH GmbH, Denali Therapeutics Inc.
Uei
WPDGJCK93HY6
  • DOL H-1B labor condition applications and PERM certifications217 data points21 Oct 2019 to 3 Aug 2026
  • Federal lobbying disclosures (LDA)1 record, 21 data points1 Jan 2025 to 30 Sep 2026
  • SEC Form 13F institutional holdings324 data points31 Dec 2017 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)125 records13 Nov 2017 to 3 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)626 data points31 Dec 2015 to 28 Oct 2026
  • SEC Form 4 insider transactions238 records, 608 data points14 Dec 2017 to 9 Sep 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026